Literature DB >> 23168012

QiShenYiQi Pills® prevent cardiac ischemia-reperfusion injury via energy modulation.

Se-Qi Lin1, Xiao-Hong Wei, Ping Huang, Yu-Ying Liu, Na Zhao, Quan Li, Chun-Shui Pan, Bai-He Hu, Xin Chang, Jing-Yu Fan, Xiao-Yuan Yang, Chaun-She Wang, Hong-Ning Liu, Jing-Yan Han.   

Abstract

BACKGROUND: QiShenYiQi Pills® (QSYQ) is a compound Chinese medicine used in China for alleviating cardiac function. The present study was designed to explore the effect and mechanism of QSYQ on ischemia-reperfusion (I/R)-induced disorders in myocardial structure and function, with particularly focusing on the regulation of energy metabolism.
METHODS: Sprague-Dawley rats, with or without QSYQ pretreatment, were subjected to 30 min occlusion of the left anterior descending coronary artery and followed by 90 min or 24h reperfusion. Myocardial blood flow (MBF) and cardiac function were evaluated at baseline, immediately after ischemia and 30, 60, 90 min, and 24h after reperfusion. Myocardial infarction, myocardial histology and ultrastructure were assessed. Double staining of alpha-cardiac actinin and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling was conducted to assess myocardial apoptosis. ATP, ADP and AMP content was determined by Enzyme-Linked Immunosorbent Assay, F-actin in myocardial cells determined by immunofluorescence microscopy and expression of ATP synthase α, ATP5D, and phosphorylated-Myosin Light Chain (P-MLC) determined by western blotting.
RESULTS: Pre-treatment with QSYQ protected against I/R-induced MBF decrease, myocardial infarction and apoptosis at 90 min and 24h after reperfusion. Moreover, I/R 90 min caused an impairment on cardiac function, a decrease in the ratio of ADP/ATP and AMP/ATP, accompanying with reduction of ATP 5D expression and increase in the expression of P-MLC, meanwhile, myocardium to exhibit myocardial fiber rupture, interstitial edema, and mitochondria swelling, all of which were significantly ameliorated by pre-treatment with QSYQ.
CONCLUSIONS: The results of the present study suggest an involvement of regulation of energy metabolism in the action of QSYQ to protect against myocardial I/R injury.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  ATP synthase subunit; Cardiac function; Cardiac injury; Mongolian milkvetch root; Salvia miltiorrhiza

Mesh:

Substances:

Year:  2012        PMID: 23168012     DOI: 10.1016/j.ijcard.2012.10.042

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  28 in total

1.  Protective effect of the traditional Chinese medicine xuesaitong on intestinal ischemia-reperfusion injury in rats.

Authors:  Xuan Xu; Dengxiao Li; Hong Gao; Yuejin Gao; Long Zhang; Yuling Du; Jian Wu; Pengfei Gao
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Effects of Qishen Yiqi Dripping Pills () in Reducing Myocardial Injury and Preserving Microvascular Function in Patients Undergoing Elective Percutaneous Coronary Intervention: A Pilot Randomized Study.

Authors:  Gui-Xin He; Jun Xie; Hao Jiang; Wei Tan; Biao Xu
Journal:  Chin J Integr Med       Date:  2017-05-03       Impact factor: 1.978

3.  Cardioprotection against ischemia/reperfusion injury by QiShenYiQi Pill® via ameliorate of multiple mitochondrial dysfunctions.

Authors:  Jing Rui Chen; Jing Wei; Ling Yan Wang; Yan Zhu; Lan Li; Mary Akinyi Olunga; Xiu Mei Gao; Guan Wei Fan
Journal:  Drug Des Devel Ther       Date:  2015-06-15       Impact factor: 4.162

4.  QiShenYiQi Pills, a compound in Chinese medicine, protects against pressure overload-induced cardiac hypertrophy through a multi-component and multi-target mode.

Authors:  Yuan-Yuan Chen; Quan Li; Chun-Shui Pan; Li Yan; Jing-Yu Fan; Ke He; Kai Sun; Yu-Ying Liu; Qing-Fang Chen; Yan Bai; Chuan-She Wang; Bing He; Ai-Ping Lv; Jing-Yan Han
Journal:  Sci Rep       Date:  2015-07-02       Impact factor: 4.379

5.  YiXin-Shu, a ShengMai-San-based traditional Chinese medicine formula, attenuates myocardial ischemia/reperfusion injury by suppressing mitochondrial mediated apoptosis and upregulating liver-X-receptor α.

Authors:  Yichao Zhao; Longwei Xu; Zhiqing Qiao; Lingchen Gao; Song Ding; Xiaoying Ying; Yuanyuan Su; Nan Lin; Ben He; Jun Pu
Journal:  Sci Rep       Date:  2016-03-11       Impact factor: 4.379

6.  Ischemic postconditioning influences electron transport chain protein turnover in Langendorff-perfused rat hearts.

Authors:  Song Cao; Yun Liu; Haiying Wang; Xiaowen Mao; Jincong Chen; Jiming Liu; Zhengyuan Xia; Lin Zhang; Xingkui Liu; Tian Yu
Journal:  PeerJ       Date:  2016-02-16       Impact factor: 2.984

7.  QiShenYiQi Attenuates Renal Interstitial Fibrosis by Blocking the Activation of β-Catenin.

Authors:  Zhanmei Zhou; Zheng Hu; Mei Li; Fengxin Zhu; Hao Zhang; Jing Nie; Jun Ai
Journal:  PLoS One       Date:  2016-09-16       Impact factor: 3.240

8.  QiShenYiQi Pill Improves Myocardial Hypertrophy Caused by Pressure Overload in Rats.

Authors:  Shichao Lv; Qiang Wang; Meifang Wu; Meng Li; Xiaojing Wang; Ling Xu; Junping Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-16       Impact factor: 2.629

9.  Qi-shen-yi-qi dripping pills for the secondary prevention of myocardial infarction: a randomised clinical trial.

Authors:  Hongcai Shang; Junhua Zhang; Chen Yao; Baoyan Liu; Xiumei Gao; Ming Ren; Hongbao Cao; Guohua Dai; Weiliang Weng; Sainan Zhu; Hui Wang; Hongjuan Xu; Boli Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-14       Impact factor: 2.629

10.  Deepure Tea Improves High Fat Diet-Induced Insulin Resistance and Nonalcoholic Fatty Liver Disease.

Authors:  Jing-Na Deng; Juan Li; Hong-Na Mu; Yu-Ying Liu; Ming-Xia Wang; Chun-Shui Pan; Jing-Yu Fan; Fei Ye; Jing-Yan Han
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-04       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.